MA26563A1 - Composes therapeutiquement actifs contenant de l'indazole en remplacement bio-isosterique du catechol, leur preparation et composition pharmaceutique les contenant - Google Patents

Composes therapeutiquement actifs contenant de l'indazole en remplacement bio-isosterique du catechol, leur preparation et composition pharmaceutique les contenant

Info

Publication number
MA26563A1
MA26563A1 MA25332A MA25332A MA26563A1 MA 26563 A1 MA26563 A1 MA 26563A1 MA 25332 A MA25332 A MA 25332A MA 25332 A MA25332 A MA 25332A MA 26563 A1 MA26563 A1 MA 26563A1
Authority
MA
Morocco
Prior art keywords
catechol
preparation
pharmaceutical composition
active compounds
therapeutically active
Prior art date
Application number
MA25332A
Other languages
English (en)
Inventor
Marfat Anthony
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26563A1 publication Critical patent/MA26563A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA25332A 1997-11-04 1998-11-03 Composes therapeutiquement actifs contenant de l'indazole en remplacement bio-isosterique du catechol, leur preparation et composition pharmaceutique les contenant MA26563A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6419897P 1997-11-04 1997-11-04
US6418797P 1997-11-04 1997-11-04
US6422897P 1997-11-04 1997-11-04
US6422997P 1997-11-04 1997-11-04
US6402497P 1997-11-04 1997-11-04

Publications (1)

Publication Number Publication Date
MA26563A1 true MA26563A1 (fr) 2004-12-20

Family

ID=27535645

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25332A MA26563A1 (fr) 1997-11-04 1998-11-03 Composes therapeutiquement actifs contenant de l'indazole en remplacement bio-isosterique du catechol, leur preparation et composition pharmaceutique les contenant

Country Status (29)

Country Link
US (1) US6391872B1 (fr)
EP (1) EP1028946A1 (fr)
JP (1) JP2001521926A (fr)
CN (1) CN1284948A (fr)
AP (1) AP910A (fr)
AR (1) AR013746A1 (fr)
AU (1) AU754734B2 (fr)
BG (1) BG104450A (fr)
BR (1) BR9813926A (fr)
CA (1) CA2309150A1 (fr)
CZ (1) CZ20001621A3 (fr)
DZ (1) DZ2640A1 (fr)
EA (1) EA200000488A1 (fr)
HR (1) HRP20000253A2 (fr)
HU (1) HUP0004150A3 (fr)
ID (1) ID23921A (fr)
IL (1) IL135900A0 (fr)
IS (1) IS5465A (fr)
MA (1) MA26563A1 (fr)
NO (1) NO20002129L (fr)
NZ (1) NZ503918A (fr)
OA (1) OA11354A (fr)
PE (1) PE129199A1 (fr)
PL (1) PL340753A1 (fr)
SK (1) SK6252000A3 (fr)
TN (1) TNSN98200A1 (fr)
TR (1) TR200001234T2 (fr)
WO (1) WO1999023077A1 (fr)
YU (1) YU25000A (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20001623A3 (cs) * 1997-11-04 2001-08-15 Pfizer Products Inc. Terapeuticky účinné látky na bázi nahrazení katecholu indazolovým bioisosterem v inhibitorech PDE4
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP2001031549A (ja) * 1999-07-14 2001-02-06 Pola Chem Ind Inc 真皮コラーゲン線維束再構築剤及びそれを含有する化粧料
NZ517120A (en) * 1999-08-12 2004-10-29 Wyeth Corp NSAID and EFGR kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US7005443B1 (en) * 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
CA2440842A1 (fr) 2001-04-16 2002-10-24 Eisai Co., Ltd. Nouveau compose a base de 1h-indazoles
CN100496607C (zh) 2001-09-19 2009-06-10 尼科梅德有限责任公司 Nsaid与pde-4抑制剂的并用药物
WO2003024456A1 (fr) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methodes de traitement et de prevention des migraines
CN1701477A (zh) * 2002-02-13 2005-11-23 皇家飞利浦电子股份有限公司 集成半导体光学设备以及制造该设备的方法和装置
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
EP1503778B1 (fr) 2002-04-30 2009-08-05 Unigen Pharmaceuticals, Inc. Formulation pour un melange de flavonoides et de flavanes sans noyau b utilise comme agent therapeutique
US8034387B2 (en) 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
DE60321958D1 (de) 2002-12-02 2008-08-14 Hoffmann La Roche Indazolderivate und ihre verwendung als crf antagonisten
TW200505904A (en) 2003-02-14 2005-02-16 Wyeth Corp Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
BRPI0409179A (pt) * 2003-04-04 2006-05-02 Unigen Pharmaceuticals Inc formulação de inibidores duplos de ciclooxigenase (cox) e lipoxigenase (lox) para cuidados com a pele de mamìferos
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
JP2007523938A (ja) 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー ピラゾールの縮合誘導体
US7844309B2 (en) * 2004-02-27 2010-11-30 Nokia Corporation Exchangeable keymat
CN1922150A (zh) 2004-02-27 2007-02-28 霍夫曼-拉罗奇有限公司 吲唑衍生物以及含有它们的药物组合物
MXPA06009462A (es) 2004-02-27 2007-03-15 Hoffmann La Roche Derivados pirazolo heteroaril fusionados.
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
BRPI0518693A2 (pt) * 2004-11-29 2008-12-02 Warner Lambert Co pirazol [3,4-b]piridinas e indazàis terapÊuticos, bem como composiÇço farmacÊutica e uso dos mesmos
EP1915348A1 (fr) * 2005-08-15 2008-04-30 Wyeth a Corporation of the State of Delaware Dérivés d azinyl-3-sulfonylindazole en tant que ligands de 5-hydroxytryptamine-6
BRPI0614343A2 (pt) * 2005-08-15 2011-03-22 Wyeth Corp derivados de 3-sulfonilindazol substituìdo como ligantes de 5-hidroxitriptamina-6
MX2008002588A (es) 2005-08-25 2008-03-18 Hoffmann La Roche Inhibidores de p38-map-cinasa y los metodos para utilizarlos.
EP1928866A1 (fr) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Indazoles substitues utilises en tant qu'inhibiteurs de phosphodiesterase de type-iv
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
WO2007056087A1 (fr) * 2005-11-03 2007-05-18 Allergan, Inc. Prostaglandines et analogues utilises en tant qu'agents pour abaisser la pression intraoculaire
MX2008009022A (es) 2006-01-13 2008-09-24 Wyeth Corp 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina.
DK1981851T3 (da) 2006-01-31 2012-03-19 Array Biopharma Inc Kinaseinhibitorer og fremgangsmåder til anvendelse deraf
JP2009528363A (ja) 2006-02-28 2009-08-06 ヘリコン セラピューティクス，インコーポレイテッド Ｐｄｅ４インヒビターとしての治療用ピペラジン
WO2007120523A2 (fr) * 2006-03-31 2007-10-25 Vitae Pharmaceuticals, Inc. 6-(aminoalkyl)indazoles
JP2009532471A (ja) * 2006-04-05 2009-09-10 ワイス ５−ヒドロキシトリプタミン−６リガンドとしてのスルホニル−３−ヘテロシクリルインダゾール誘導体
WO2007120596A1 (fr) * 2006-04-12 2007-10-25 Wyeth DÉRIVÉS DE DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE EN TANT QUE LIGANDS DE 5-HYDROXYTRYPTAMINE-6
US8012886B2 (en) * 2007-03-07 2011-09-06 Asm Assembly Materials Ltd Leadframe treatment for enhancing adhesion of encapsulant thereto
KR101568884B1 (ko) 2007-03-14 2015-11-12 랜박시 래보러터리스 리미티드 포스포디에스테라제 저해제로서 피라졸로 (３,４-ｂ) 피리딘 유도체
CN102648284B (zh) * 2009-09-18 2014-09-24 株式会社里维松 多酚衍生物及其制造方法
MX2012013197A (es) 2010-05-12 2013-04-03 Abbvie Inc Inhibidores de indazol de cinasa.
CN103709146B (zh) * 2014-01-15 2015-11-25 中国药科大学 一类含苯并咪唑结构的喹啉-4-胺衍生物、其制法及医药用途
WO2021138391A1 (fr) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Composés d'indazole
US12264149B2 (en) 2020-12-30 2025-04-01 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003385A1 (fr) * 1987-10-13 1989-04-20 Yoshitomi Pharmaceutical Industries, Ltd. Composes de pyrazole fusionnes, procede de preparation et utilisation en medecine
EP0338087A4 (en) * 1987-10-13 1991-07-24 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrazole compounds, process for their preparation, and their medicinal use
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
AU716376B2 (en) * 1996-06-25 2000-02-24 Pfizer Inc. Substituted indazole derivatives and their use as phosphodiesterase (PDE) type IV and tumor necrosis factor (TNF) inhibitors
ES2168581T3 (es) * 1996-06-27 2002-06-16 Pfizer Derivados de indazol sustituidos.
CN1234031A (zh) * 1996-09-04 1999-11-03 辉瑞大药厂 吲唑衍生物及其作为磷酸二酯酶(pde)iv型和肿瘤坏死因子(tnf)产生的抑制剂的应用
CZ20001623A3 (cs) * 1997-11-04 2001-08-15 Pfizer Products Inc. Terapeuticky účinné látky na bázi nahrazení katecholu indazolovým bioisosterem v inhibitorech PDE4

Also Published As

Publication number Publication date
TR200001234T2 (tr) 2000-08-21
SK6252000A3 (en) 2001-11-06
EP1028946A1 (fr) 2000-08-23
HRP20000253A2 (en) 2001-06-30
US6391872B1 (en) 2002-05-21
ID23921A (id) 2000-05-25
EA200000488A1 (ru) 2000-10-30
CZ20001621A3 (cs) 2001-08-15
CA2309150A1 (fr) 1999-05-14
DZ2640A1 (fr) 2003-03-08
BR9813926A (pt) 2000-09-19
AU9455298A (en) 1999-05-24
TNSN98200A1 (fr) 2005-03-15
HUP0004150A2 (hu) 2001-05-28
BG104450A (en) 2000-12-29
CN1284948A (zh) 2001-02-21
NZ503918A (en) 2002-03-28
NO20002129D0 (no) 2000-04-26
YU25000A (sh) 2003-12-31
AP9801375A0 (en) 1998-12-31
NO20002129L (no) 2000-07-03
JP2001521926A (ja) 2001-11-13
AP910A (en) 2000-12-05
HUP0004150A3 (en) 2001-08-28
OA11354A (en) 2003-12-23
AU754734B2 (en) 2002-11-21
PL340753A1 (en) 2001-02-26
WO1999023077A1 (fr) 1999-05-14
PE129199A1 (es) 1999-12-16
IL135900A0 (en) 2001-05-20
AR013746A1 (es) 2001-01-10
IS5465A (is) 2000-04-19

Similar Documents

Publication Publication Date Title
MA26563A1 (fr) Composes therapeutiquement actifs contenant de l'indazole en remplacement bio-isosterique du catechol, leur preparation et composition pharmaceutique les contenant
MA23632A1 (fr) Procede de preparation de composes nouveaux et de compostions pharmaceutiques les contenant
MA26562A1 (fr) Composes therapeutiquement actifs bases sur le remplacement bio-isosterique du catechol par l'indazole dans des inhibiteurs de pde4, leur procede de production et composition pharmaceutique les contenant.
MA26571A1 (fr) Derives d'acide hydroxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
DZ2523A1 (fr) Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation.
DZ2303A1 (fr) Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA23834A1 (fr) Procede de preparation de composes inhibiteurs de l'enzyme lp-pla2 et de compositions pharmaceutiques les contenant
DZ2745A1 (fr) BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2581A1 (fr) Dérivés d'acides aryloxyarylsulfonylaminohydroxamiques procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2407A1 (fr) Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant
MA26428A1 (fr) Derives d'indole nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
SK284171B9 (sk) Derivát 4''-substituovaného-9-deoxo-9a-aza-9a-homoerytromycínu A, spôsob a medziprodukty na jeho prípravu, jeho použitie a farmaceutická kompozícia s jeho obsahom
FR2729951B1 (fr) Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
DZ2045A1 (fr) Amides thérapeutiques, procédé pour leur préparation et compositions les contenant.
DZ2538A1 (fr) Tartrate d'un dipeptide substitué procédé pour sa préparation et compositions pharmaceutiques le contenant.
EE04238B1 (et) Asendatud 1,2,3,4-tetrahüdronaftaleeni derivaadid, meetod selle valmistamiseks, nimetatud terapeutilise toimega aineid sisaldavad ravimkoostised ja nimetatud aktiivsete ühendite kasutamine teraapias
DZ2550A1 (fr) Dérivés d'azétidinylpropylpipéridine procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2737721B1 (fr) Nouveaux composes biphenyles, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicament et les compositions pharmaceutiques les contenant
DZ2655A1 (fr) Trifluorométhyléthers cycliques à fonction pipéridinylaminoéthyle procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2414A1 (fr) 2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2763337B1 (fr) Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2624A1 (fr) Dérivés d'isoquinoléine nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26631A1 (fr) Composes a fonction bis-aminomethyl-carbonyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2719593B1 (fr) Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.